NPC1L1 Recombinant Monoclonal Antibody

說明書

中文名稱：

NPC1L1重組抗體
貨號：

CSB-RA921474A0HU
規格：

￥1320
圖片：
IHC image of CSB-RA921474A0HU diluted at 1:100 and staining in paraffin-embedded human liver tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

NPC1L1重組單克隆抗體（CSB-RA921474A0HU）是針對膽固醇吸收關鍵調控蛋白NPC1L1開發的高特異性檢測工具。該靶點在腸道和肝臟中高表達，通過介導膳食膽固醇的內吞作用參與脂質代謝調控，是心血管疾病及代謝綜合征研究的重點分子。本抗體采用重組技術制備，經ELISA和免疫組化（IHC）雙重驗證，在IHC實驗中推薦使用1:50-1:200的稀釋比例，可清晰顯示組織切片中NPC1L1蛋白的定位與表達水平。適用于探究膽固醇吸收機制、構建脂代謝疾病模型以及降脂類藥物作用機理等基礎研究領域，為體外實驗提供穩定可靠的檢測支持。其單克隆特性確保了檢測結果的高重復性，滿足細胞實驗、病理分析等科研場景中對靶標蛋白定量與定性分析的需求。
Uniprot No.：

Q9UHC9
基因名：

NPC1L1
別名：

NPC1-like intracellular cholesterol transporter 1 (Niemann-Pick C1-like protein 1), NPC1L1
反應種屬：

Human
免疫原：

A synthesized peptide derived from human NPC1L1
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

4B10
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Plays a major role in cholesterol homeostasis. Is critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte. Is the direct molecular target of ezetimibe, a drug that inhibits cholesterol absorption. Lack of activity leads to multiple lipid transport defects. The protein may have a function in the transport of multiple lipids and their homeostasis, and may play a critical role in regulating lipid metabolism. Acts as a negative regulator of NPC2 and down-regulates its expression and secretion by inhibiting its maturation and accelerating its degradation.
基因功能參考文獻：
1. The results obtained from liver-specific NPC1L1 transgenic mouse (L1-Tg) crossed with LDLR-/- mouse indicated no feedback mechanism to inhibit NPC1L1 function in liver and hepatic expression of NPC1L1 correlated with VLDL secretion in hypercholesterolemia state. PMID: 29601818
2. Lifelong, genetic inhibition of NPC1L1, mimicking treatment with ezetimibe, does not associate with risk of cancer. PMID: 29106532
3. Due to their high affinity for the N-terminal domain of NPC1L1, black and cowpea bean peptides produced in the digestive track have the potential to disrupt interactions between NPC1L1 and membrane proteins that lead to cholesterol absorption PMID: 28259659
4. These experiments demonstrate that cholesterol uptake by NPC1L1 does not require endocytosis; moreover, ezetimibe interferes with NPC1L1's cholesterol adsorption activity without blocking NPC1L1 internalization in RH7777 cells. PMID: 27075173
5. Novel sequencing techniques are detecting rare variants with larger effect sizes (eg, NPC1L1) , which may further improve on Cardiovascular disease risk prediction. PMID: 27650930
6. The results demonstrate that NPC1L1 recognizes alpha-tocopherol via its N-terminal domain and mediates alpha-tocopherol uptake through the same mechanism as cholesterol absorption. PMID: 28315682
7. Simultaneously, these data indicate that R174H, V177I and V1284L NPC1L1 variations in high or low LDL-C individuals may not directly influence cholesterol absorption by NPC1L1. PMID: 27697530
8. The results of this study identified the association between genetic susceptibility of the NPC1L1 gene and HCV infection, as well as biochemical characteristics of HCV-infected persons in Yunnan, China. PMID: 27769799
9. exposure to LDL-C-lowering genetic variants in or near NPC1L1 and other genes was associated with a higher risk of type 2 diabetes. These data provide insights into potential adverse effects of LDL-C-lowering therapy. PMID: 27701660
10. Detailed analysis of the role of NPC1L1 mutations in an exceptional responder to ezetimibe. The results point to a complex set of events in which the combined mutations were shown to affect cholesterol uptake in the presence of ezetimibe. Proteomic analysis suggests that the exceptional response may also lie in the nature of interactions with cytosolic proteins. PMID: 26761771
11. Study suggests that the G allele of the NPC1L1 polymorphism g1679C>G may be a positive marker of gallstone formation risk. PMID: 26800364
12. To study whether human NPC1L1 gene is regulated transcriptionally by LRH-1, we have analyzed evolutionary conserved regions (ECRs) in HepG2 cells. PMID: 25739390
13. No significant association between investigated NPC1L1 variants and risk of coronary atherosclerosis could be observed. PMID: 26253792
14. Results show that genetic variation in NPC1L1 is associated with a reduction in risk of IVD, with a corresponding reduction in LDL cholesterol, but with a concomitant increased risk of gallstone disease PMID: 25841872
15. The frequencies of NPC1L1 polymorphisms in Chinese Hans are comparable to Japanese population but totally different from Caucasians, African-Americans and Hispanic individuals PMID: 26492642
16. demonstrate that Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter, plays a central role in intestinal VK uptake and modulates the anticoagulant effect of warfarin. In PMID: 25696002
17. Lipid-lowering response to ezetimibe is not impacted by the NPC1L1 polymorphisms studied in Chilean hypercholesterolemic subjects. PMID: 25589339
18. NPC1L1-mediated cholesterol absorption is a major determinant of blood levels of apolipoprotein B-containing atherogenic lipoproteins PMID: 25463095
19. The effect of lower LDL-C on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both is approximately the same per unit lower LDL-C and log-linearly proportional to the absolute exposure to lower LDL-C. PMID: 25770315
20. NPC1L1 polymorphism is associated with sitosterolaemia. PMID: 25056759
21. Our study is the first report concerning the genotype and allele frequencies of the gene coding for NPC1L1 in Japanese patients with dyslipidemia. PMID: 24861377
22. DNA methylation in the promoter region of the NPC1L1 gene appears to be a major mechanism underlying differential expression of NPC1L1 along the length of the gastrointestinal tract. PMID: 24904062
23. Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease. PMID: 25390462
24. Endoplasmic reticulum-associated degradation of Niemann-Pick C1: evidence for the role of heat shock proteins and identification of lysine residues that accept ubiquitin. PMID: 24891511
25. NPC1L1-133A > G SNP influences the ApoA1 response to ezetimibe monotherapy PMID: 24974575
26. Herein, authors identify the host cell hepatitis C virus entry factor NPC1L1 as also being required for hepatitis C virus cell-to-cell spread. PMID: 24554660
27. in patients with hyperlipidemias, G allele of NPC1L1 and APO E4 could account for some of the inter-individual variability in cholesterol absorption PMID: 23415434
28. Glucose appears to directly modulate NPC1L1 expression via transcriptional mechanisms and the involvement of phosphatase-dependent pathways. PMID: 23139223
29. The present study suggests that the rs2072183 SNP in NPC1L1 gene and its association with serum lipid profiles are different between the Mulao and Han populations. PMID: 22646906
30. Lutein absorption is, at least in part, mediated by influx transporters NPC1L1 and SR-B1 rather than mediated by efflux transporters such as ABC (ATP-binding cassette) transporters PMID: 22579005
31. NPC1L1 down-regulates the expression and secretion of NPC2 by inhibiting its maturation and accelerating its degradation. Hepatic NPC1L1 may control cholesterol homeostasis via the down-regulation of NPC2. PMID: 22095670
32. the mechanism of cholesterol sensing by NPC1L1 and proposes a mechanism for selective cholesterol absorption PMID: 21602275
33. These findings demonstrated a direct role of hepatic NPC1L1 in regulating biliary cholesterol excretion and hepatic/blood cholesterol levels, and unequivocally established hepatic NPC1L1 as a target of ezetimibe. PMID: 21683156
34. The structure of NPC1L1(NTD) reveals a degree of flexibility surrounding the entrance to the sterol binding pocket. PMID: 21525977
35. PPARalpha positively regulates human NPC1L1 transcription via direct binding to a PPRE. Additionally, PGC1alpha stimulates the SREBP2/HNF4alpha- and PPARalpha/RXRalpha- mediated transactivation of human NPC1L1 PMID: 20953676
36. dysfunction of the 19 variants on cholesterol absorption is due to the impairment of recycling, subcellular localization, glycosylation, or stability of NPC1L1 PMID: 21189420
37. inhibition of NPC1L1 by ezetimibe is effective in non-obese patients with nonalcoholic fatty liver disease PMID: 20222991
38. hepatic NPC1L1 in the liver from Chinese female gallstone patients may be mediated by SREBP2 PMID: 20144195
39. Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1 PMID: 19443194
40. The transport activity of NPC1L1 variants between cholesterol and alpha-tocopherol, were compared. PMID: 19823104
41. Single nucleotide polymorphism in NPC1L1 is associated with enhanced cholesterol absorption from the intestine. PMID: 20379057
42. regulation by SREBP2 and HNF1alpha on the NPC1L1 promoter activity PMID: 20460578
43. NPC1L1 gene is associated with plasma total and LDL-C levels and coronary heart disease risk. PMID: 19752398
44. NPC1L1 promoter variants might explain in part the hypercholesterolemic phenotype of some subjects with non-LDL receptor/apolipoprotein B autosomal dominant hypercholesterolemia PMID: 19747803
45. The -762C allele of NPC1L1 had a higher promoter activity and was associated with a higher serum total cholesterol and LDL-cholesterol level. PMID: 19265861
46. expression is enriched in the small intestine and is in the brush border membrane of enterocytes PMID: 14976318
47. NPC1L1 has a role in lipid transport and in diet-induced hypercholesterolemia PMID: 15671032
48. DNA sequence variants in NPC1L1 are associated with an improvement in response to ezetimibe, a cholesterol absorption inhibitor demonstrated to reduce LDL-cholesterol. PMID: 16297596
49. nonsynonymous variant technique to demonstrate that genetic variation in NPC1L1 contributes to variability in cholesterol absorption and plasma levels of low-density lipoproteins PMID: 16449388
50. Intestinal gene expression is altred in type 2 diabetees. Diabetic patients have more NPC1L1 mRNA than the control subjects. PMID: 16518588
顯示更多

收起更多
亞細胞定位：

Apical cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein. Cytoplasmic vesicle membrane; Multi-pass membrane protein.
蛋白家族：

Patched family
組織特異性：

Widely expressed. Expressed in liver. Also expressed in small intestine, pancreas, kidney, lung, pancreas, spleen, heart, gall bladder, brain, testis, stomach and muscle.
數據庫鏈接：

HGNC: 7898

OMIM: 608010

KEGG: hsa:29881

STRING: 9606.ENSP00000289547

UniGene: Hs.567486

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat